Physician profile
Thomas M Dodge
NPI 1164767471
$2,003.23
in general payments reported to CMS, 2019-2025
17 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 88% of Psychiatric/Mental Health, Child & Family providers received nationally (typical 2025 total: $178).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $34.56 · 2023: $333 · 2024: $629 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879 · Education: $89.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,879.32 |
| Education | $89.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $414.80 | 2023-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $286.61 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $271.34 | 2022-2025 | Caplyta |
| Abbvie INC. | $171.28 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $156.64 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $148.42 | 2025 | Fanapt |
| Tris Pharma INC | $86.02 | 2024-2025 | Dyanavel Xr |
| Lundbeck LLC | $84.08 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $81.83 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $50.61 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $48.74 | 2023-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $47.45 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $46.07 | 2024 | Relexxii |
| Corium, LLC | $40.85 | 2024-2025 | Azstarys |
| Alkermes, INC. | $32.44 | 2023-2025 | Aristada, Vivitrol, Lybalvi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $18.85 | 2024 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $17.20 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.